Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma

被引:41
|
作者
Moratin, Julius [1 ]
Metzger, Karl [1 ]
Safaltin, Ayse [1 ]
Herpel, Esther [2 ,3 ]
Hoffmann, Juergen [1 ]
Freier, Kolja [1 ,4 ]
Hess, Jochen [5 ,6 ]
Horn, Dominik [1 ,4 ]
机构
[1] Heidelberg Univ Hosp, Dept Oral & Craniomaxillofacial Surg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany
[3] Natl Ctr Tumor Dis NCT, Tissue Bank, Heidelberg, Germany
[4] Saarland Univ Hosp, Dept Oral & Maxillofacial Surg, Homburg, Germany
[5] Heidelberg Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Heidelberg, Germany
[6] German Canc Res Ctr, Res Grp Mol Mech Head & Neck Tumors, Heidelberg, Germany
关键词
HNSCC; immune checkpoint; lymph node metastases; PD-L1; PD-L2; EXPRESSION; RECURRENT; PEMBROLIZUMAB; PATHWAY; RECOGNITION; PROGRESSION; DISSECTION; RESISTANCE; RELEVANCE; NIVOLUMAB;
D O I
10.1002/hed.25713
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background This study aimed on evaluating the expression levels of the immune checkpoint proteins, PD-L1 and PD-L2, in tissue specimens of 175 oral squamous cell carcinomas (OSCC) and 33 corresponding lymph node metastases (LNM). Methods Tissue microarrays of primary OSCC and matched LNM were investigated via immunohistochemistry regarding PD-L1/PD-L2 expression. Results were compared for primary tumors and corresponding metastases and correlated with clinicopathological data. Results PD-L1 expression in cancer cells correlated significantly with tumor size, and the presence of regional metastases (P < 0.01). PD-L1 expression was significantly higher in metastases as compared to primary OSCC (P < 0.05). Overall survival was significantly worse in patients with higher levels of PD-L1 and PD-L2 score (P < 0.05). Conclusions This is the first publication to compare PD-L1 and PD-L2 expression in primary OSCC and matched LNM. The results indicate that anti-PD-1 therapy may be of therapeutic use even in early stage OSCC to prevent further progression.
引用
收藏
页码:2484 / 2491
页数:8
相关论文
共 50 条
  • [11] Significance of PD-L1 testing in Outcome of Head and Neck Squamous Cell Carcinoma
    Bancu, A.
    Preetha, C.
    JOURNAL OF PATHOLOGY, 2021, 255 : S26 - S26
  • [12] Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
    Rasmussen, Jacob H.
    Lelkaitis, Giedrius
    Hakansson, Katrin
    Vogelius, Ivan R.
    Johannesen, Helle H.
    Fischer, Barbara M.
    Bentzen, Soren M.
    Specht, Lena
    Kristensen, Claus A.
    von Buchwald, Christian
    Wessel, Irene
    Friborg, Jeppe
    BRITISH JOURNAL OF CANCER, 2019, 120 (10) : 1003 - 1006
  • [13] PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
    Mueller, Tim
    Braun, Martin
    Dietrich, Dimo
    Aktekin, Seher
    Hoeft, Simon
    Kristiansen, Glen
    Goeke, Friederike
    Schroeck, Andreas
    Braegelmann, Johannes
    Held, Stefanie A. E.
    Bootz, Friedrich
    Brossart, Peter
    ONCOTARGET, 2017, 8 (32) : 52889 - 52900
  • [14] Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
    Jiang, Siqing
    Li, Xin
    Huang, Lihua
    Xu, Zhensheng
    Lin, Jinguan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [15] The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment
    Pai, Sara I.
    Zandberg, Dan P.
    Strome, Scott E.
    ORAL ONCOLOGY, 2016, 61 : 152 - 158
  • [16] Differences in PD-L1, PD-L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study
    Sato, Ryosuke
    Inoue, Takahiro
    Wakisaka, Risa
    Komatsuda, Hiroki
    Kono, Michihisa
    Yamaki, Hidekiyo
    Ohara, Kenzo
    Kumai, Takumi
    Kosaka, Akemi
    Ohkuri, Takayuki
    Nagato, Toshihiro
    Kishibe, Kan
    Kobayashi, Hiroya
    Takahara, Miki
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025,
  • [17] Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma
    Huang, Shuang
    Xiong, Chuang
    Tan, Kui
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2023, 44 (06)
  • [18] Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD-L1 and PD-L2
    Sato, Ryosuke
    Komatsuda, Hiroki
    Inoue, Takahiro
    Wakisaka, Risa
    Kono, Michihisa
    Yamaki, Hidekiyo
    Ohara, Kenzo
    Kumai, Takumi
    Kishibe, Kan
    Hayashi, Tatsuya
    Takahara, Miki
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (09): : 2233 - 2243
  • [19] Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma
    de Ruiter, E.
    Mulder, F.
    Speel, E.
    van den Hout, M.
    de Roest, R.
    Bloemena, E.
    Devriese, L.
    Willems, S.
    VIRCHOWS ARCHIV, 2019, 475 : S90 - S91
  • [20] Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry
    Mishra, Prabha S.
    Sidhu, Avnit
    Dwivedi, Gunjan
    Mulajker, Deepak S.
    Awasthi, Shivali
    INDIAN JOURNAL OF CANCER, 2022, 59 (04) : 474 - 479